|Articles|July 11, 2012

Drug Cost Control in Oncology

Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Clinical trial phases. | Image credit: @OlivierLeMoal.jpeg

FAQ: Kalshi's Cancer Drug Betting Markets Raise Ethics Concerns

BySabrina McCrear

September 4th 2026

Doctor and patient | Image credit: Chinnapong - stock.adobe.com

Advance Planning Eases Bispecific Therapy Burden for Patients

ByLaura Joszt, MA

September 4th 2026

Andrew Kuykendall, MD | Image Credit: Moffitt Cancer Center

Rusfertide Approval Aims to Close PV Hematocrit Control Gaps

ByAndrew Kuykendall, MD,Maggie L. Shaw

September 4th 2026

Dr Christos Vaklavas | Image Credit: University of Utah

Resource Demands Challenge Community Oncology: Christos Vaklavas, MD

ByBrooke McCormick,Christos Vaklavas, MD

September 3rd 2026

Dr Amandeep Godara | Image Credit: University of Utah

Access, Logistics Shape Multiple Myeloma Immunotherapy Decisions

ByBrooke McCormick,Amandeep Godara, MBBS

September 3rd 2026

Drug Cost Control in Oncology

Related Content

FAQ: Kalshi's Cancer Drug Betting Markets Raise Ethics Concerns

Advance Planning Eases Bispecific Therapy Burden for Patients

Rusfertide Approval Aims to Close PV Hematocrit Control Gaps

Resource Demands Challenge Community Oncology: Christos Vaklavas, MD

Access, Logistics Shape Multiple Myeloma Immunotherapy Decisions

Trending on AJMC

Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD

Health Equity & Access Weekly Roundup: September 4, 2026